The Borody Protocol – 2020-08 – Prophylactic COVID-19 Treatment

Prophylaxis with Ivermectin in exposed people. Dr. Gustavo Aguirre-Chang.

Results on a community intervention trial

Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lucia Romani, Ph,D. Michael Marks, PhD Oliver Sokana, MPH Titus Nasi, MCHBakaai Kamoriki Billie Cordell, MPH The Lancet. Volume 19, ISSUE 5, P510-518, May 01, 2019

The overall decrease in outpatient attendance for reported communicable diseases from the 3 months before to the 3 months after mass drug administration was 40·7% (95% CI 39·6–41·8, table 5). A larger decrease was observed for presentations categorised as skin sores, boils, and abscesses (50·9%, 95% CI 48·6–53·1) than for any other presentation of disease. When comparing the 3-month period 12 months before mass drug administration (October to December, 2014) with the 3-month period after (October to December, 2015), we observed a large decrease in attendance for communicable diseases (55·8%, 95% CI 54·8–56·7; appendix).

“In the AIM trial, ivermectin plus antibiotic mass drug administration was highly effective at decreasing scabies and impetigo prevalence at 12 months after the intervention in a population of over 25 000 people in a province in the Solomon Islands. Other substantial short-term health benefits were observed, with notable decreases in all-cause outpatient clinic attendance and presentations for multiple communicable diseases.”…